已发表论文

丙泊酚单药与丙泊酚联合芬太尼用于上消化道内镜检查的有效性和安全性:一项随机、双盲、对照试验

 

Authors Liu L, Li F, Wei Y, Luo L, Shen L, Li J, Sun N, Qian B, Sun D 

Received 7 January 2025

Accepted for publication 13 June 2025

Published 18 June 2025 Volume 2025:19 Pages 5231—5241

DOI https://doi.org/10.2147/DDDT.S516064

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Qiongyu Guo

Lu Liu,1 Feng Li,1 Yanxia Wei,2 Li Luo,1 Li Shen,1 Jie Li,1 Ninglin Sun,1 Bin Qian,1 Dawei Sun3 

1Department of Anesthesiology, The First People’s Hospital of Yancheng, Yancheng, Jiangsu, People’s Republic of China; 2Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Anesthesiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

Correspondence: Dawei Sun, Department of Anesthesiology, The Second Affiliated Hospital, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, People’s Republic of China, Tel +86-19557123453, Email Sundaweide@163.com Bin Qian, Department of Anesthesiology, The First People’s Hospital of Yancheng, 166 Yulong West Road, Yancheng, 224006, People’s Republic of China, Tel +86-13858007629, Email 985578655@qq.com

Background: Ciprofol is increasingly used in surgical procedures, and anesthesiologists have observed that it provides deeper sedation compared to propofol. However, it remains unclear whether the use of ciprofol alone, without combining opioids, is sufficient for upper gastrointestinal endoscopy. This study aims to address this question.
Objective: To determine whether ciprofol alone is non-inferior to ciprofol combined with fentanyl regarding sedation success and safety.
Methods: In this randomized, double-blind trial, 344 adult patients (ASA I–II, aged 18– 70 years) undergoing elective upper gastrointestinal endoscopy were randomized to receive either ciprofol with saline (CS group) or ciprofol with fentanyl (CF group). Participants in both groups received an initial ciprofol dose of (0.4 mg/kg). The CF group received (1 μg/kg) intravenously before ciprofol administration, while the CS group received an equivalent volume of saline. Additional ciprofol doses (0.15– 0.30 mg/kg) were administered as needed. The primary outcome was sedation success, defined as procedure completion with no more than two additional ciprofol doses within any 5-minute interval. Secondary outcomes included the incidence of hypotension and hypoxemia, as well as adverse events.
Results: Sedation success rates were 99.4% for CS and 100% for CF, demonstrating non-inferiority (difference: − 0.6%, 95% CI: − 0.02, 0.01). The CS group had lower respiratory depression rates and better hemodynamic stability but higher intraoperative coughing (18.1% vs 2.9%, P=0.01). Induction and recovery times were slightly longer in the CS group, and postoperative dizziness was more common (15.2% vs 7%, P=0.03).
Conclusion: Ciprofol alone is non-inferior to ciprofol with fentanyl for sedation in upper gastrointestinal endoscopy and offers advantages in respiratory and hemodynamic stability. However, it is associated with increased coughing, minor delays in induction and recovery, and more postoperative dizziness.

Keywords: ciprofol, upper gastrointestinal endoscopy, sedation, hypotension, hypoxemia, opioid-sparing